Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Predicting Response to Therapy for Graft-vs-Host Disease (GvHD) with a Rapid Immune Function Assay.

Elias J. Anaissie, MD, Jose A. Diaz, MD, Monica L. Grazziutti, MD, Marisa H. Miceli, MD, Michele Fox-Cottler, MD, Bart Barlogie, MD, Frits van Rhee, MD

Blood (2007) 110 (11): 5012.

https://doi.org/10.1182/blood.V110.11.5012.5012

Published: 2007

Journal Articles

Monitoring Immune Function in the Allogeneic Transplant Recipient: Predicting Graft vs Host Disease (GvHD) and Infection.

Elias J. Anaissie, MD, Jose A. Diaz, MD, Monica L. Grazziutti, MD, Marisa H. Miceli, MD, Michele Fox-Cottler, MD, Bart Barlogie, MD, Frits van Rhee, MD

Blood (2007) 110 (11): 1966.

https://doi.org/10.1182/blood.V110.11.1966.1966

Published: 2007

Journal Articles

Predicting Risk of Infection and Graft vs. Host Disease (GvHD), and Response to Immunosuppression (ISP) in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Patients (pts) Using the Cylex®ImmuKnow® Assay: A Pilot Study.

Elias J. Anaissie, Jose A. Diaz, Monica L. Grazziutti, Marisa H. Miceli, Michele Fox-Cottler, Bart Barlogie

Blood (2006) 108 (11): 5325.

https://doi.org/10.1182/blood.V108.11.5325.5325

Published: 2006

Journal Articles

Low Frequency of Treatment-Related Myelodysplastic Syndromes (t-MDS) after Autotransplants (AT) for Multiple Myeloma (MM), Especially If AT Is Applied Early during Treatment.

Guido Tricot, Maureen Reiner, Jeffrey Sawyer, Elias Anaissie, Frits van Rhee, Maurizio Zangari, Klaus Hollmig, Gordon Dewald, Michele Fox, Bart Barlogie

Blood (2005) 106 (11): 706.

https://doi.org/10.1182/blood.V106.11.706.706

Published: 2005

Journal Articles

Complete Response (CR) with Total Therapy 2 (TT2) for Multiple Myeloma (MM): Low Frequency in Case of Prior MGUS without Adverse Consequences for Survival - Yet Critical for Disease Control in Presumed “De Novo” MM.

Athanasios Fassas, Erik Rasmussen, John Shaughnessy, Guido Tricot, Maurizio Zangari, Frits van Rhee, Elias Anaissie, Klaus Hollmig, Michele Fox, Joshua Epstein, John Crowley, Bart Barlogie

Blood (2005) 106 (11): 1172.

https://doi.org/10.1182/blood.V106.11.1172.1172

Published: 2005

Journal Articles

NY-ESO-1 Specific Antibodies Are Frequently Detected in Hight-Risk Myeloma.

Frits van Rhee, MD, PhD, Susann M. Szmania, BS, Mindy Pomtree, Frank Zhan, Amberly Moreno, BS, Nancy Rosen, Michele Fox, MD, Bart Barlogie, MD, PhD, John Shaughnessy, PhD, Ramesh Batchu, PhD, Guido J. Tricot, MD, PhD

Blood (2004) 104 (11): 2464.

https://doi.org/10.1182/blood.V104.11.2464.2464

Published: 2004

NARROW

Predicting Response to Therapy for Graft-vs-Host Disease (GvHD) with a Rapid Immune Function Assay.

Monitoring Immune Function in the Allogeneic Transplant Recipient: Predicting Graft vs Host Disease (GvHD) and Infection.

Predicting Risk of Infection and Graft vs. Host Disease (GvHD), and Response to Immunosuppression (ISP) in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Patients (pts) Using the Cylex®ImmuKnow® Assay: A Pilot Study.

Low Frequency of Treatment-Related Myelodysplastic Syndromes (t-MDS) after Autotransplants (AT) for Multiple Myeloma (MM), Especially If AT Is Applied Early during Treatment.

Complete Response (CR) with Total Therapy 2 (TT2) for Multiple Myeloma (MM): Low Frequency in Case of Prior MGUS without Adverse Consequences for Survival - Yet Critical for Disease Control in Presumed “De Novo” MM.

NY-ESO-1 Specific Antibodies Are Frequently Detected in Hight-Risk Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Predicting Response to Therapy for Graft-vs-Host Disease (GvHD) with a Rapid Immune Function Assay.

Monitoring Immune Function in the Allogeneic Transplant Recipient: Predicting Graft vs Host Disease (GvHD) and Infection.

Predicting Risk of Infection and Graft vs. Host Disease (GvHD), and Response to Immunosuppression (ISP) in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Patients (pts) Using the Cylex®ImmuKnow® Assay: A Pilot Study.

Low Frequency of Treatment-Related Myelodysplastic Syndromes (t-MDS) after Autotransplants (AT) for Multiple Myeloma (MM), Especially If AT Is Applied Early during Treatment.

Complete Response (CR) with Total Therapy 2 (TT2) for Multiple Myeloma (MM): Low Frequency in Case of Prior MGUS without Adverse Consequences for Survival - Yet Critical for Disease Control in Presumed “De Novo” MM.

NY-ESO-1 Specific Antibodies Are Frequently Detected in Hight-Risk Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only